Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of fibrotic lung disease, including idiopathic pulmonary fibrosis (IPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.
OUR SCIENCE
Our approach is embodied in our pipeline of potential therapies that precisely target the root cause of disease to deliver transformational clinical benefits and the potential to change treatment expectations.
Our leadership team has deep experience developing drug candidates into leading medicines that make a meaningful difference in patients’ lives.
OUR LEADERSHIP
OUR CULTURE
We have a vibrant and passionate culture that reflects our shared mission to deliver new therapeutic options for patients with life-threatening diseases.
LATEST NEWS
Endeavor BioMedicines Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
SAN DIEGO – May 1, 2025 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that two posters have been accepted for presentation at the American Thoracic Society 2025 (ATS 2025) International Conference. ATS 2025 will...
Endeavor BioMedicines Appoints Internationally Renowned ILD Expert Lisa Lancaster, M.D., as Chief Medical Officer
SAN DIEGO – April 2, 2025 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Lisa Lancaster, M.D., as Chief Medical Officer. A renowned pulmonologist and clinical researcher focused on interstitial lung...
First Patient Dosed in Endeavor BioMedicines’ Phase 2b WHISTLE-PF Trial Evaluating ENV-101 for the Treatment of Idiopathic Pulmonary Fibrosis
- ENV-101, a novel investigational Hedgehog signaling pathway inhibitor, has demonstrated clinical potential to improve lung function and total lung capacity, and reverse multiple key quantitative measures of lung fibrosis SAN DIEGO – November 20, 2024 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational...
Fibrotic Lung Disease
ENV-101 has the potential to be the first-ever disease-modifying therapy for pulmonary fibrosis, including IPF.
Oncology
ENV-501 is an optimized next-generation anti-HER3 antibody-drug conjugate with the potential to treat multiple tumor types.